Articles from Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF).

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings.

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update.

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings.

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it has completed enrollment for its lead program in a Phase 2 clinical trial of TTI-101 for patients with idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial of TTI-101 in patients suffering from IPF. Key endpoints include safety and lung function (FVC).

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, NY.

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.

Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that an abstract will be presented at the American Thoracic Society 2025 Annual Conference, which is being held May 16-21 in San Francisco.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, announced today that John Kauh, M.D., Chief Medical Officer, will present a poster at the CHEST 2024 Annual Meeting, which is being held October 6-9, in Boston, Massachusetts. The American College of Chest Physicians (CHEST) is the global leader in advancing patient outcomes through innovative chest medicine education, clinical research and team-based care.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrotic diseases, chronic inflammatory diseases and diverse cancers, today announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics, was selected to make a presentation and co-lead a panel discussion at the 8th Annual IPF Summit being held in Boston, MA on August 22, 2024.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D. has been added to the Board of Directors.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will participate at the Cowen 44th Annual Health Care Conference with the management team holding one-on-one investor meetings on March 4, 2024.

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced it will present a trials in progress poster at the upcoming 2024 ASCO Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in San Francisco, CA. The poster will highlight the design of the ongoing REVERT LIVER CANCER study, a Phase 1b/2 trial evaluating safety and clinical activity of TTI-101, a novel STAT3 inhibitor, as monotherapy and in combination with standard of care in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28, 2023, and will participate in one-on-one meetings with investors throughout the day, in New York, NY.

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the first patients have been dosed in its ongoing REVERTIPF trial. The trial is a 12-week, randomized, double-blind study evaluating both safety and clinical activity of TTI-101 at three different doses, alone or in combination with nintedanib (OFEV®), compared to placebo in patients with idiopathic pulmonary fibrosis (IPF).

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that the first patients have been dosed in each arm of its ongoing REVERT LIVER CANCER trial. The trial is evaluating safety and clinical activity of TTI-101 as monotherapy and in combination with standard of care therapy in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the company has been invited to participate at the Cowen 43rd Annual Health Care Conference. The management team will hold one-on-one meetings on March 8, 2023, to review emerging clinical data.

Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the first breast cancer patients have been dosed in the Phase 1b/2 REVERT trial of TTI-101 added to palbociclib and aromatase inhibitor (AI) therapy in adult patients with HR+/HER2- palbociclib-resistant metastatic breast cancer. The first patients were dosed at the Washington University School of Medicine Siteman Cancer Center by Cynthia Ma, MD, PhD, Professor of Medicine, Clinical Director of the Breast Cancer Program, Section of Medical Oncology.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the Guggenheim Securities Oncology Conference on Wednesday, February 8, 2023, in New York City as well as host one-on-one meetings throughout the day.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, in San Francisco, CA.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will present at the 34th Annual Piper Sandler Healthcare Conference at 1:50 p.m. ET on Thursday, December 1, 2022, in New York City as well as host one-on-one meetings throughout the day.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma (HCC).

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 1:30 p.m. ET as well as in one-on-one meetings in New York City on Wednesday, September 14, 2022.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that management will participate in one-on-one meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day. The conference is being held in a virtual format on Tuesday, May 3rd, 2022.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced its collaborators will present preclinical data demonstrating TTI-101 overcomes palbociclib resistance in metastatic breast cancer murine models at the upcoming 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, LA, from April 8th – 13th, 2022. The study was led by Khandan Keyomarsi, PhD, Professor of Experimental Radiation Oncology at The University of Texas MD Anderson Cancer Center.

Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, has closed a $74 million Series B financing. The financing was led by new investors Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital, with continued support and participation by existing investors, including Sporos Bioventures. In conjunction with the financing, Jamie McNab, Partner at Slate Path Capital, will join the Tvardi Board of Directors.